Endometrial hyperplasia screening: Difference between revisions
Jump to navigation
Jump to search
Badria Munir (talk | contribs) |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Endometrial hyperplasia}} | {{Endometrial hyperplasia}} | ||
{{CMG}}{{AE}} {{ | {{CMG}}{{AE}} {{Swathi}} | ||
==Oveview== | ==Oveview== | ||
Routine screening for endometrial hyperplasia or endometrial carcinoma is not recommended. | Routine [[Screening (medicine)|screening]] for [[endometrial]] [[hyperplasia]] or [[endometrial]] [[carcinoma]] is not recommended. | ||
==Screening== | ==Screening== | ||
* Women receiving unopposed [[Estrogen|estrogens]] should undergo [[endometrial]] sampling once every 2 years. <ref name="pmid1893367">{{cite journal |vauthors=Hakala T, Mecklin JP, Forss M, Järvinen H, Lehtovirta P |title=Endometrial carcinoma in the cancer family syndrome |journal=Cancer |volume=68 |issue=7 |pages=1656–9 |date=October 1991 |pmid=1893367 |doi= |url=}}</ref> | * [[Women]] receiving unopposed [[Estrogen|estrogens]] should undergo [[endometrial]] [[sampling]] once every 2 [[Year|years]]. <ref name="pmid1893367">{{cite journal |vauthors=Hakala T, Mecklin JP, Forss M, Järvinen H, Lehtovirta P |title=Endometrial carcinoma in the cancer family syndrome |journal=Cancer |volume=68 |issue=7 |pages=1656–9 |date=October 1991 |pmid=1893367 |doi= |url=}}</ref> | ||
* Particularly if [[endometrial]] hyperstimulation was documented previously and is not been treated by short-term progestins. | * Particularly if [[endometrial]] hyperstimulation was documented previously and is not been treated by short-term [[progestins]]. | ||
* If high-risk individual requests an [[endometrial]] evaluation before or during [[HRT]]. | * If high-risk individual requests an [[endometrial]] evaluation before or during [[HRT]]. | ||
* Women at high risk for [[Endometrial cancer|endometrial carcinoma]], such as history of [[Lynch II syndrome]]. | * [[Women]] at high risk for [[Endometrial cancer|endometrial carcinoma]], such as history of [[Lynch II syndrome]]. | ||
==References== | ==References== | ||
Latest revision as of 13:12, 8 May 2019
|
Endometrial hyperplasia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Endometrial hyperplasia screening On the Web |
|
American Roentgen Ray Society Images of Endometrial hyperplasia screening |
|
Risk calculators and risk factors for Endometrial hyperplasia screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Swathi Venkatesan, M.B.B.S.[2]
Oveview
Routine screening for endometrial hyperplasia or endometrial carcinoma is not recommended.
Screening
- Women receiving unopposed estrogens should undergo endometrial sampling once every 2 years. [1]
- Particularly if endometrial hyperstimulation was documented previously and is not been treated by short-term progestins.
- If high-risk individual requests an endometrial evaluation before or during HRT.
- Women at high risk for endometrial carcinoma, such as history of Lynch II syndrome.